AB-1005 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AB-1005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AB-1005 overview

Gene therapy is under development for the treatment of Parkinson's disease and multiple system atrophy. The drug candidate comprises of an adeno-associated virus serotype 2 (AAV2) vector carrying the glial cell derived neurotrophic factor (GDNF) gene. It is administered by parenteral route. It is developed based on Adeno-associated virus vector (AAV) technology.

Asklepios BioPharmaceutical overview

Asklepios BioPharmaceutical (AskBio) is AAV gene therapy development company. It develops and markets novel protein and cellular-based therapies. The company’s product pipeline includes therapies for the treatment of neuromuscular, central nervous system, heart-related diseases including pompe, limb-girdle 2i, huntington’s, multiple system atrophy, parkinson’s, and congestive heart failure (nanocor). AskBio has developed library of AAV biological nanoparticles that provides unsurpassed transduction. It serves pharmaceutical and biotechnology companies. AskBio is headquartered in Durham, North Carolina, the US.

For a complete picture of AB-1005’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.